{"denoms":[{"counts":[{"groupId":"BG000","value":"10"}],"units":"Participants"}],"groups":[{"description":"Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0","id":"BG000","title":"V-BEAM + Stem Cell Infusion"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"48","upperLimit":"69","value":"64.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Stage IIA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Stage IIIA"}],"description":"STAGE I\n\n* Hemoglobin \\>10g/dL\n* Serum calcium normal or \\<10.5mg/dL\n* Bone x-ray, normal bone structure (scale 0), or solitary bone plasmacytoma only\n* Low M-component production rates IgG value \\<5g/dL; IgA value \\<3g/dL\n* Urine light chain M-component on electrophoresis \\<4g/24h\n\nSTAGE II -Neither Stage I or Stage III\n\nSTAGE III\n\n* Hemoglobin \\<8.5g/dL\n* Serum calcium \\>12mg/dL\n* Advanced lytic bone lesions (scale 3) -High M-component production rates IgG value \\>7g/dL IgA value \\>5g/dL- Bence Jones protein \\>12g/24h\n\nSUBCLASS\n\n-A: relatively normal renal function (serum creatinine) \\<2.0 mg/dL","paramType":"NUMBER","title":"Durie-Salmon Stage of Myeloma on Diagnosis","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Unknown"}],"description":"STAGE I\n\n-Serum beta-2 microglobulin is less than 3.5 (mg/L) and the albumin level is above 3.5 (g/L)\n\nSTAGE II -Neither stage I or III\n\nSTAGE III\n\n-Serum beta-2 microglobulin is greater than 5.5","paramType":"NUMBER","title":"International Staging System (ISS) Stage of Myeloma on Diagnosis","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"IgG"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"IgA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Light chain only"}],"description":"Antibodies typically consist of 2 heavy chains and 2 light chains. There are 5 kinds of heavy chains termed IgG, IgA, IgM, IgD, and IgE; and 2 distinct types of light chain, termed kappa and lambda. In myeloma, all the abnormal plasma cells make the same antibody. Therefore the myeloma can be classified by the type of light and heavy chains produced, such as IgG kappa, IgG lambda, IgA kappa, or IgA lambda, etc.\n\nOccasionally, the malignant plasma cells make only the light chain component of the antibody. These patients are said to have \"light chain myeloma.\"","paramType":"NUMBER","title":"Monoclonal Protein Type","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"17","upperLimit":"97","value":"29"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time to Progression from First Transplant","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"27","upperLimit":"118","value":"42"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time from Diagnosis to V-BEAM transplant","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"3","upperLimit":"6","value":"4"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Number of Prior Therapies (including prior transplant)","unitOfMeasure":"prior therapies"}]}